In Vitro Activity of Cefaclor/Beta-Lactamases Inhibitors (Clavulanic Acid and Sulbactam) Combination Against Extended-Spectrum Beta-Lactamase Producing Uropathogenic E. coli
I tiakina i:
| I whakaputaina i: | Antibiotics vol. 14, no. 6 (2025), p. 603 |
|---|---|
| Kaituhi matua: | |
| Ētahi atu kaituhi: | , , , , , |
| I whakaputaina: |
MDPI AG
|
| Ngā marau: | |
| Urunga tuihono: | Citation/Abstract Full Text + Graphics Full Text - PDF |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3223866836 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2079-6382 | ||
| 024 | 7 | |a 10.3390/antibiotics14060603 |2 doi | |
| 035 | |a 3223866836 | ||
| 045 | 2 | |b d20250101 |b d20251231 | |
| 084 | |a 231335 |2 nlm | ||
| 100 | 1 | |a Atoom Ali |u Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan; bayann2000@gmail.com (B.A.); danabarakat46@gmail.com (D.B.); ranaabugheyab@gmail.com (R.A.-G.); daloubaidy@yahoo.com (D.I.-A.) | |
| 245 | 1 | |a In Vitro Activity of Cefaclor/Beta-Lactamases Inhibitors (Clavulanic Acid and Sulbactam) Combination Against Extended-Spectrum Beta-Lactamase Producing Uropathogenic <i>E. coli</i> | |
| 260 | |b MDPI AG |c 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Background: Urinary tract infections (UTIs) caused by the multidrug resistance (MDR) phenotype termed extended-spectrum beta lactamase (ESBL)-producing E. coli is a significant and growing global health concern. In response to the rising prevalence, the novel Beta Lactam-Beta Lactamase inhibitor (BL/BLI) combinations have been introduced in recent years. While these agents have shown efficacy, their clinical utility is constrained by high cost, limited availability, and emerging resistance mechanisms. The rational of this study was to test the in vitro activity of a cost-effective alternative to currently available BL–BLI combinations against ESBL-producing E. coli isolated from urinary tract infections (UTIs). Objective: This study investigates the in vitro antimicrobial activity of cefaclor (CFC), both as monotherapy and in combination with the β-lactamase inhibitors clavulanic acid (CA) and sulbactam (SUL), against 52 ESBL-producing E. coli isolates derived from urine cultures of patients diagnosed with UTIs. Methods: The susceptibility ranges were measured by disk diffusion and minimal inhibitory concentration (MIC) methods. In addition, the Time kill assay and disk approximation method were performed to measure the synergistic and bactericidal activity of the approached combination. Results: The MIC50 and MIC90 for CFC were improved from more than 128 µg/mL to 8/4 µg/mL when CFC was combined with either CA or SUL. The triple combination format of CFC/CA/SUL showed MIC50 and MIC90 values at 8/4/4 µg/mL and 64/32/32 µg/mL, respectively. The recovered susceptibility percentages were 54%, 54%, and 58% for CFC/CA, CFC/SUL, and CFC/CA/SUL combinations, respectively. Disk approximation and time–kill assay results revealed synergy and bactericidal effects when CFC combined with CA or SUL for isolates that showed susceptibility restorations of CFC when coupled with CA or SUL by the disk diffusion and MIC method. Conclusions: This study proposes a cost-effective combination that could mitigate resistance development and offer a sparing option to last resort treatment choices including carbapenems. However, testing efficacy in a clinical setting is crucial. | |
| 653 | |a Urogenital system | ||
| 653 | |a In vitro methods and tests | ||
| 653 | |a Sulbactam | ||
| 653 | |a Urinary tract | ||
| 653 | |a Acids | ||
| 653 | |a Public health | ||
| 653 | |a Phenotypes | ||
| 653 | |a Bacteria | ||
| 653 | |a Clavulanic acid | ||
| 653 | |a Approximation | ||
| 653 | |a Availability | ||
| 653 | |a E coli | ||
| 653 | |a Amides | ||
| 653 | |a Cefaclor | ||
| 653 | |a Genotype & phenotype | ||
| 653 | |a Multidrug resistance | ||
| 653 | |a Cost effectiveness | ||
| 653 | |a Bactericidal activity | ||
| 653 | |a Urinary tract diseases | ||
| 653 | |a Urinary tract infections | ||
| 653 | |a Inhibitors | ||
| 653 | |a Approximation method | ||
| 653 | |a Minimum inhibitory concentration | ||
| 653 | |a Bacterial infections | ||
| 653 | |a Antimicrobial agents | ||
| 653 | |a Carbapenems | ||
| 653 | |a Global health | ||
| 653 | |a Streptococcus infections | ||
| 653 | |a Enzymes | ||
| 653 | |a β Lactamase | ||
| 653 | |a Antimicrobial activity | ||
| 700 | 1 | |a Alzubi Bayan |u Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan; bayann2000@gmail.com (B.A.); danabarakat46@gmail.com (D.B.); ranaabugheyab@gmail.com (R.A.-G.); daloubaidy@yahoo.com (D.I.-A.) | |
| 700 | 1 | |a Barakat, Dana |u Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan; bayann2000@gmail.com (B.A.); danabarakat46@gmail.com (D.B.); ranaabugheyab@gmail.com (R.A.-G.); daloubaidy@yahoo.com (D.I.-A.) | |
| 700 | 1 | |a Abu-Gheyab, Rana |u Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan; bayann2000@gmail.com (B.A.); danabarakat46@gmail.com (D.B.); ranaabugheyab@gmail.com (R.A.-G.); daloubaidy@yahoo.com (D.I.-A.) | |
| 700 | 1 | |a Ismail-Agha, Dalia |u Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan; bayann2000@gmail.com (B.A.); danabarakat46@gmail.com (D.B.); ranaabugheyab@gmail.com (R.A.-G.); daloubaidy@yahoo.com (D.I.-A.) | |
| 700 | 1 | |a Al-Kaabneh Awatef |u Princess Iman Center for Research and Laboratory Sciences, Jordanian Royal Medical Services, Amman 11855, Jordan; awatef.kaabneh@jrms.gov.jo | |
| 700 | 1 | |a Numan Nawfal |u College of Pharmacy, The University of Mashreq, Baghdad 10023, Iraq; nawfal.am.numan@uom.edu.iq | |
| 773 | 0 | |t Antibiotics |g vol. 14, no. 6 (2025), p. 603 | |
| 786 | 0 | |d ProQuest |t Biological Science Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3223866836/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text + Graphics |u https://www.proquest.com/docview/3223866836/fulltextwithgraphics/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3223866836/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |